AI Revolutionizes Drug Development, Offering Opportunities for K-Bio Growth

Artificial intelligence (AI) is transforming industries, and the pharmaceutical and biotechnology sectors are at a significant turning point. Historically, drug development has been a costly and time-consuming endeavor, often described as a 'game of chance.' It typically takes an average of 10 to 15 years and billions of won to bring a single candidate drug to market, with a success rate of just one in ten thousand. However, AI is changing this long-standing paradigm. The focus of drug development is shifting from trial-and-error in laboratories to predictive science driven by data and algorithms.

AI is already deeply integrated into the entire drug development process. It analyzes vast amounts of research papers and clinical data to identify disease causes, selects promising candidate compounds from millions, and even predicts the likelihood of clinical trial success. Tasks that once took years can now be completed in months or even weeks. This innovation goes beyond mere efficiency improvements; it fundamentally alters the economics of drug development.

For the South Korean biotechnology industry, AI is not just an option but a necessity. While the country boasts world-class medical infrastructure and information and communication technology (ICT) capabilities, it lacks the research and development capital of global pharmaceutical giants. To compete in the global market, South Korea must adopt an 'ultra-gap strategy' utilizing AI. AI serves as a powerful tool to overcome limitations in scale.

Domestic biotech companies are actively engaging in AI-driven drug development. The use of AI in candidate drug discovery and clinical trial design is increasing, and collaborations with global pharmaceutical companies are expanding. If South Korea can enhance development speed and reduce failure costs through AI, it could transition from being a manufacturing powerhouse focused on biosimilars and contract development and manufacturing organizations (CDMO) to a leader in innovative drug development.

To achieve this, building AI infrastructure is crucial. High-performance computing resources, cloud environments, and bio-specialized data platforms are necessary for training large AI models. The United States and China are investing in AI infrastructure at the national level to compete for dominance in biotechnology. South Korea must also move beyond relying solely on individual companies and actively pursue the establishment of a national AI bio platform. An open ecosystem connecting research institutions, businesses, and hospitals needs to be fostered.

Regulatory innovation is equally important. Most current regulations were established in an era before AI existed. The verification processes for candidate substances identified by AI, AI-based clinical trial designs, and standards for utilizing medical data remain uncertain. Excessive regulation can stifle innovation, while ambiguous guidelines can deter corporate investment. A flexible regulatory framework that ensures safety and ethics while keeping pace with technological advancements is essential.

Countries around the world are already nurturing AI and biotechnology as strategic national industries. The competition is shifting from individual companies to national ecosystems. The South Korean biotechnology industry stands at a critical crossroads. Manufacturing capabilities alone will not lead to global market leadership. To truly become a biotechnology powerhouse, it must secure the ability to develop innovative drugs using AI.

Just as semiconductors once served as the engine of South Korea's economic growth, the AI-driven biotechnology sector could become a new growth driver for the future. AI is a game changer that can redefine drug development. What is now needed is a belief in the potential of technology and the establishment of national strategies and execution capabilities. The combination of AI and biotechnology may create a new success story that leads the South Korean economy for the next 30 years.

* This article has been translated by AI.